Form 4: 10x Genomics Executive Benjamin J. Hindson Reports Acquisition of Restricted Stock Units

Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, reports the acquisition of 71,083 restricted stock units.

Summary

• On March 21, 2024, Benjamin J. Hindson, President and Chief Scientific Officer of 10x Genomics, acquired 71,083 restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Class A Common Stock upon vesting.
• 1/16th of the RSUs will vest on each quarterly anniversary measured from February 21, 2024, contingent upon Hindson's continued service.
• Following the transaction, Hindson directly owns 354,142 shares of Class A Common Stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a routine transaction (RSU grant) that aligns executive interests with shareholders, but doesn't contain any groundbreaking news.

Positives

• The acquisition of RSUs by a key executive like Benjamin J. Hindson can be seen as a positive sign, aligning his interests with the company's long-term success.

Future Outlook

The vesting schedule of the RSUs indicates a continued commitment from Benjamin J. Hindson to 10x Genomics over the coming years.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the ownership structure and alignment of interests between executives and shareholders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment, as it signals continued commitment from a key executive.

Key Dates